Acer Therapeutics Pauses ACER-801 Program After Trial Misses Topline Results [MarketWatch]
Acer Therapeutics Inc. (ACER)
Last acer therapeutics inc. earnings: 3/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
acertx.com/investor-relations
Company Research
Source: MarketWatch
severe vasomotor symptoms associated with menopause didn't achieve statistical significance even though it was safe and well-tolerated. The Newton, Mass.-based pharmaceutical company said the Phase 2a clinical trial evaluated ACER-801's ability to decrease the frequency or severity of hot flashes in postmenopausal women. As a result of missing the topline results, Acer Therapeutics is pausing the ACER-801 program until it has conducted a thorough review of the full data set. Acer Therapeutics said it is continuing to focus on an ongoing Phase 3 clinical trial of Edsivo for the treatment of vascular Ehlers-Danlos Syndrome, as well as on the commercial launch of an oral suspension of Olpruva sodium phenylbutyrate for the treatment of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase. Acer shares were down 29% to $1.10 in premarket trading Friday. Write to Chris Wack at chris.wack@wsj.com
Show less
Read more
Impact Snapshot
Event Time:
ACER
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACER alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACER alerts
High impacting Acer Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ACER
News
- Acer Therapeutics Inc. (NASDAQ: ACER) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswire
- Acer Therapeutics stock dips on $2.7M securities offering [Seeking Alpha]Seeking Alpha
- Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment AttributesGlobeNewswire
- Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswire
ACER
Earnings
- 8/15/22 - Beat
ACER
Analyst Actions
- 3/29/23 - HC Wainwright
ACER
Sec Filings
- 3/27/23 - Form S-8
- 3/27/23 - Form 10-K
- 3/27/23 - Form 8-K
- ACER's page on the SEC website